Abstract Library

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,

#3727 PREF-NET: A patient preference and experience study of lanreotide autogel (LAN) administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the UK

Introduction: The somatostatin analogue LAN is a common first-line treatment for NETs that can be given at home in a ready-to-use syringe every 4 weeks in the UK.

Conference:

Presenting Author: Khan M

Authors: Khan M, Davies L, Back M, Shah T, Pritchard D,

Keywords: patient participation, somatostatin analogues, injections, quality of life, value-based health care,

#3648 Treatment preferences for somatostatin analogues in neuroendocrine tumors (NETs) among patients, clinicians and nurses in Australia

Introduction: Long-acting somatostatin analogues (LA SSAs) are commonly used as first-line treatment in low-grade pancreatic or midgut neuroendocrine tumors (NETs). Due to the long-term nature of treatment, treatment preferences should be taken into consideration. Funding for this study was provided by Ipsen.

Conference:

Presenting Author:

Authors: Cummins M, Fifer S, Winkler K, Cherian H,

Keywords: Treatment preferences, LA SSAs, NET,

#3500 HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,

#3288 Not waving but drowning?

Introduction: The disruptive impact COVID19 has had on cancer care availability and resources may yet have far-reaching consequences, physically and mentally, for those with neuroendocrine Cancer.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Jervis N

Authors: Jervis N,

Keywords: support, unmet needs, psychosocial care, impact of COVID,